Skip to content

Statin Effect on ARrhythmogenic CardiomyopatHy disease progression

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514643-28-00
Acronym
SEARCH
Enrollment
102
Registered
2024-10-11
Start date
2025-03-25
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmogenic Cardiomyopathy (ACM)

Brief summary

Deterioration from baseline of RV free wall longitudinal strain measured by ECHO

Detailed description

Deterioration from baseline of i) arrhythmia burden (PVC, non-sustained and sustained VA, VF, appropriate ICD shocks); ii) other morphological parameters (ventricular volumes, function, both at ECHO and CMR); iii) ECG parameters; iv) blood parameters, Monitoring of AE

Interventions

DRUGAtorvastatina Teva Italia 80 mg compresse rivestite con film
DRUGwhite
DRUGshaped elliptical
DRUGand coated with smooth film. The dimensions of each tablet are approximately 18.8 mm x 10.3 mm (identical to those containing atorvastatin).

Sponsors

Centro Cardiologico Monzino S.p.A.
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Deterioration from baseline of RV free wall longitudinal strain measured by ECHO

Secondary

MeasureTime frame
Deterioration from baseline of i) arrhythmia burden (PVC, non-sustained and sustained VA, VF, appropriate ICD shocks); ii) other morphological parameters (ventricular volumes, function, both at ECHO and CMR); iii) ECG parameters; iv) blood parameters, Monitoring of AE

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026